Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2010, Article ID 923743, 8 pages
http://dx.doi.org/10.1155/2010/923743
Review Article

Digital Ischemia in Scleroderma Spectrum of Diseases

Division of Rheumatology, University of Michigan Scleroderma Program, 24 Frank Lloyd Wright Drive, Ann Arbor, MI 48106, USA

Received 16 May 2010; Accepted 8 July 2010

Academic Editor: Lorinda Chung

Copyright © 2010 Elena Schiopu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. M. Wigley and N. A. Flavahan, “Raynaud's phenomenon,” Rheumatic Disease Clinics of North America, vol. 22, no. 4, pp. 765–781, 1996. View at Google Scholar
  2. A. L. Herrick, C. Roberts, and C. Roberts, “Lack of agreement between rheumatologists in defining digital ulceration in systemic sclerosis,” Arthritis and Rheumatism, vol. 60, no. 3, pp. 878–882, 2009. View at Publisher · View at Google Scholar · View at PubMed
  3. J. H. Korn, M. Mayes, and M. Mayes, “Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist,” Arthritis and Rheumatism, vol. 50, no. 12, pp. 3985–3993, 2004. View at Publisher · View at Google Scholar · View at PubMed
  4. L. Amanzi, F. Braschi, G. Fiori et al., “Digital ulcers in scleroderma: staging, characteristics and sub-setting through observatoin of 1614 digital lesions,” Rheumatology, vol. 49, no. 7, pp. 1374–1382, 2010. View at Publisher · View at Google Scholar · View at PubMed
  5. G. P. Rodnan, R. L. Myerowitz, and G. O. Justh, “Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud's phenomenon,” Medicine, vol. 59, no. 6, pp. 393–408, 1980. View at Google Scholar
  6. D. Carvalho, C. O. S. Savage, C. M. Black, and J. D. Pearson, “IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro: induction of adhesion molecule expression and involvement of endothelium-derived cytokines,” The Journal of Clinical Investigation, vol. 97, no. 1, pp. 111–119, 1996. View at Google Scholar
  7. R. Sgonc, M. S. Gruschwitz, G. Boeck, N. Sepp, J. Gruber, and G. Wick, “Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95,” Arthritis and Rheumatism, vol. 43, no. 11, pp. 2550–2562, 2000. View at Publisher · View at Google Scholar
  8. C. S. Lau, M. McLaren, A. Saniabadi, and J. J. F. Belch, “Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with or without systemic sclerosis,” Scandinavian Journal of Rheumatology, vol. 22, no. 3, pp. 97–101, 1993. View at Google Scholar
  9. F. M. Wigley, J. H. Korn, and J. H. Korn, “Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis,” Arthritis and Rheumatism, vol. 41, no. 4, pp. 670–677, 1998. View at Publisher · View at Google Scholar
  10. J. E. Pope and N. Bellamy, “Sample size calculations in scleroderma: a rational approach to choosing outcome measurements in scleroderma trials,” Clinical and Investigative Medicine, vol. 18, no. 1, pp. 1–10, 1995. View at Google Scholar
  11. K. P. Tiev, E. Diot, P. Clerson et al., “Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: post-hoc analysis of a nationwide multicenter cohort (ItinerAIR-Sclerodermie),” The Journal of Rheumatology, vol. 36, no. 7, pp. 1470–1476, 2009. View at Publisher · View at Google Scholar · View at PubMed
  12. C. Sunderkotter, I. Herrgott, and I. Herrgott, “Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors,” British Journal of Dermatology, vol. 160, no. 4, pp. 835–843, 2009. View at Publisher · View at Google Scholar · View at PubMed
  13. M. Sebastiani, A. Manfredi, M. Colaci, R. Damico, V. Malagoli, D. Giuggioli, and C. Ferri, “Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients,” Arthritis Care and Research, vol. 61, no. 5, pp. 688–694, 2009. View at Publisher · View at Google Scholar · View at PubMed
  14. E. Hachulla, P. Clerson, D. Launay, M. Lambert, S. Morell-Dubois, V. Queyrel, and P.-Y. Hatron, “Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study,” The Journal of Rheumatology, vol. 34, no. 12, pp. 2423–2430, 2007. View at Google Scholar
  15. K. Ingraham and V. Steen, “Morbidity of digital tip ulceration in scleroderma (abstract),” Arthritis and Rheumatism, vol. 54, supplement 9, p. 578, 2006. View at Google Scholar
  16. V. Steen, C. P. Denton, J. E. Pope, and M. Matucci-Cerinic, “Digital ulcers: overt vascular disease in systemic sclerosis,” Rheumatology, vol. 48, pp. 19–24, 2009. View at Google Scholar
  17. A. Impens et al., “An exploration and analysis of the current approach to ischemically threatened digit,” Clinical and Experimental Rheumatology, SP.2.270, 104, 2010.
  18. M. Matucci-Cerinic and J. R. Seibold, “Digital ulcers and outcomes assessment in scleroderma,” Rheumatology, vol. 47, supplement 5, pp. 46–47, 2008. View at Google Scholar
  19. A. E. Thompson, B. Shea, V. Welch, D. Fenlon, and J. E. Pope, “Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis,” Arthritis and Rheumatism, vol. 44, no. 8, pp. 1841–1847, 2001. View at Publisher · View at Google Scholar
  20. M. Rademaker, E. D. Cooke, N. E. Almond, J. A. Beacham, R. E. Smith, T. G. K. Mant, and J. D. Kirby, “Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study,” British Medical Journal, vol. 298, no. 6673, pp. 561–564, 1989. View at Publisher · View at Google Scholar
  21. R. Fries, K. Shariat, H. Von Wilmowsky, and M. Böhm, “Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy,” Circulation, vol. 112, no. 19, pp. 2980–2985, 2005. View at Publisher · View at Google Scholar · View at PubMed
  22. J. Gore and R. Silver, “Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis,” Annals of the Rheumatic Diseases, vol. 64, no. 9, p. 1387, 2005. View at Publisher · View at Google Scholar · View at PubMed
  23. C. L. Colglazier, P. G. Sutej, and K. S. O'Rourke, “Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil,” Journal of Rheumatology, vol. 32, no. 12, pp. 2440–2442, 2005. View at Google Scholar
  24. C. Brueckner, M. O. Becker, T. Kroencke et al., “Effect of Sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study,” Annals of the Rheumatic Diseases, 2009. View at Publisher · View at Google Scholar · View at PubMed
  25. P. Shenoy, V. Agarwal, S. Kumar et al., “Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double blind randomized cross over trial,” Arthritis and Rheumatism, vol. 58, supplement 9, p. S402, 2008. View at Google Scholar
  26. E. Schiopu, V. M. Hsu, and V. M. Hsu, “Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis,” The Journal of Rheumatology, vol. 36, no. 10, pp. 2264–2268, 2009. View at Publisher · View at Google Scholar · View at PubMed
  27. M. L. Biondi, B. Marasini, C. Bassani, and A. Agostoni, “Increased plasma endothelin levels in patients with Raynaud's phenomenon,” The New England Journal of Medicine, vol. 324, no. 16, pp. 1139–1140, 1991. View at Google Scholar
  28. K. Yamane, T. Miyauchi, N. Suzuki, T. Yuhara, T. Akama, H. Suzuki, and H. Kashiwagi, “Significance of plasma endothelin-1 levels in patients with systemic sclerosis,” The Journal of Rheumatology, vol. 19, no. 10, pp. 1566–1571, 1992. View at Google Scholar
  29. N. Selenko-Gebauer, N. Duschek, G. Minimair, G. Stingl, and F. Karlhofer, “Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan,” Rheumatology, vol. 45, supplement 3, pp. 45–48, 2006. View at Publisher · View at Google Scholar · View at PubMed
  30. D. Launay, É. Diot, and É. Diot, “Bosentan for treatment of active digital ulcers in patients with systemic sclerosis,” Presse Medicale, vol. 35, no. 4, pp. 587–592, 2006. View at Publisher · View at Google Scholar
  31. P. García de la Peña-Lefebvre, S. Rodríguez Rubio, M. Valero Expósito et al., “Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients,” Rheumatology, vol. 47, no. 4, pp. 464–466, 2008. View at Google Scholar
  32. P. P. Sfikakis, C. Papamichael, and C. Papamichael, “Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis,” Arthritis and Rheumatism, vol. 56, no. 6, pp. 1985–1993, 2007. View at Publisher · View at Google Scholar · View at PubMed
  33. C. Black et al., “Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis: open lable extension to a double-blind trial,” Annals of Rheumatic Diseases, vol. 65, supplement 2, p. 384, 2006. View at Google Scholar
  34. J. Seibold et al., “Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis,” Annals of Rheumatic Diseases, vol. 65, supplement 2, p. 90, 2006. View at Google Scholar
  35. A. Ambach, W. Seo, B. Bonnekoh, and H. Gollnick, “Low-dose combination therapy of severe digital ulcers in diffuse progressive systemic sclerosis with the endothelin-1 receptor antagonist bosentan and the phosphodiesterase v inhibitor sildenafil,” Journal der Deutschen Dermatologischen Gesellschaft, vol. 7, no. 10, pp. 888–891, 2009. View at Publisher · View at Google Scholar · View at PubMed
  36. P. Gholam, T. Sehr, A. Enk, and M. Hartmann, “Successful treatment of systemic-sclerosis-related digital ulcers with a selective endothelin type A receptor antagonist (sitaxentan),” Dermatology, vol. 219, no. 2, pp. 171–173, 2009. View at Publisher · View at Google Scholar · View at PubMed
  37. D. B. Badesch, V. F. Tapson, and V. F. Tapson, “Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial,” Annals of Internal Medicine, vol. 132, no. 6, pp. 425–434, 2000. View at Google Scholar
  38. F. M. Wigley, R. A. Wise, and R. A. Wise, “Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double- blind study,” Annals of Internal Medicine, vol. 120, no. 3, pp. 199–206, 1994. View at Google Scholar
  39. F. M. Wigley, J. H. Korn, and J. H. Korn, “Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study,” Arthritis and Rheumatism, vol. 41, no. 4, pp. 670–677, 1998. View at Publisher · View at Google Scholar
  40. C. M. Black, L. Halkier-Sørensen, and L. Halkier-Sørensen, “Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study,” British Journal of Rheumatology, vol. 37, no. 9, pp. 952–960, 1998. View at Google Scholar
  41. M. Vayssairat, H. Levesque, E. Hachulla et al., “Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon,” The Journal of Rheumatology, vol. 23, no. 11, pp. 1917–1920, 1996. View at Google Scholar
  42. L. Chung and D. Fiorentino, “A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis,” Journal of the American Academy of Dermatology, vol. 54, no. 5, pp. 880–882, 2006. View at Publisher · View at Google Scholar · View at PubMed
  43. E. Schiopu et al., “Pharmacokinetics of oral treprostinil in patients with systemic sclerosis (SSc) and digital Ulcer disease,” Arthritis and Rheumatism, vol. 60, no. 10, p. S174, 2009. View at Google Scholar
  44. M. Kuwana, J. Kaburaki, Y. Okazaki, H. Yasuoka, Y. Kawakami, and Y. Ikeda, “Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis,” Arthritis and Rheumatism, vol. 54, no. 6, pp. 1946–1951, 2006. View at Publisher · View at Google Scholar · View at PubMed
  45. A. Abou-Raya, S. Abou-Raya, and M. Helmii, “Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers,” The Journal of Rheumatology, vol. 35, no. 9, pp. 1801–1808, 2008. View at Google Scholar
  46. A. E. Gliddon, C. J. Doré, and C. J. Doré, “Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril,” Arthritis and Rheumatism, vol. 56, no. 11, pp. 3837–3846, 2007. View at Publisher · View at Google Scholar · View at PubMed
  47. M. Dziadzio, C. P. Denton, R. Smith, K. Howell, A. Blann, E. Bowers, and C. M. Black, “Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial,” Arthritis and Rheumatism, vol. 42, no. 12, pp. 2646–2655, 1999. View at Publisher · View at Google Scholar
  48. P. Sambo, D. Amico, R. Giacomelli, M. Matucci-Cerinic, F. Salsano, G. Valentini, and A. Gabrielli, “Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study,” The Journal of Rheumatology, vol. 28, no. 10, pp. 2257–2262, 2001. View at Google Scholar
  49. E. Rosato, F. Borghese, S. Pisarri, and F. Salsano, “The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients,” Clinical Rheumatology, vol. 28, no. 12, pp. 1379–1384, 2009. View at Publisher · View at Google Scholar · View at PubMed
  50. E. R. Bogoch and D. K. Gross, “Surgery of the hand in patients with systemic sclerosis: outcomes and considerations,” The Journal of Rheumatology, vol. 32, no. 4, pp. 642–648, 2005. View at Google Scholar
  51. D. S. Ruch, M. Holden, B. P. Smith, T. L. Smith, and L. A. Koman, “Periarterial sympathectomy in scleroderma patients: intermediate-term follow-up,” The Journal of Hand Surgery, vol. 27, no. 2, pp. 258–264, 2002. View at Publisher · View at Google Scholar
  52. S. V. Kotsis and K. C. Chung, “A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia,” The Journal of Rheumatology, vol. 30, no. 8, pp. 1788–1792, 2003. View at Google Scholar
  53. M. Hasegawa, Y. Nagai, A. Tamura, and O. Ishikawa, “Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis,” British Journal of Dermatology, vol. 155, no. 6, pp. 1159–1164, 2006. View at Publisher · View at Google Scholar · View at PubMed
  54. J. H. Park, Y.-K. Sung, S.-C. Bae, S.-Y. Song, H. S. Seo, and J.-B. Jun, “Ulnar artery vasculopathy in systemic sclerosis,” Rheumatology International, vol. 29, no. 9, pp. 1081–1086, 2009. View at Publisher · View at Google Scholar · View at PubMed
  55. M. H. Taylor, J. A. McFadden, M. B. Bolster, and R. M. Silver, “Ulnar artery involvement in systemic sclerosis (scleroderma),” The Journal of Rheumatology, vol. 29, no. 1, pp. 102–106, 2002. View at Google Scholar